Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation

RATIONALE: Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Daniel Rødbro, Madsen, Martin Korsbak, Szabo, Attila, Aripaka, Sagar Sanjay, Stenbæk, Dea Siggaard, Frokjaer, Vibe G., Elfving, Betina, Mikkelsen, Jens D., Knudsen, Gitte Moos, Fisher, Patrick MacDonald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761602/
https://www.ncbi.nlm.nih.gov/pubmed/36545240
http://dx.doi.org/10.1016/j.cpnec.2022.100163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761602/
https://www.ncbi.nlm.nih.gov/pubmed/36545240
http://dx.doi.org/10.1016/j.cpnec.2022.100163

Ejemplares similares